|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LGALS2 |
Gene summary for LGALS2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LGALS2 | Gene ID | 3957 |
| Gene name | galectin 2 | |
| Gene Alias | HL14 | |
| Cytomap | 22q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | P05162 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3957 | LGALS2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.37e-13 | 5.91e-01 | -0.1954 |
| 3957 | LGALS2 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.38e-04 | 8.76e-01 | -0.2602 |
| 3957 | LGALS2 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.44e-04 | 3.07e-01 | -0.1464 |
| 3957 | LGALS2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.66e-03 | 5.17e-01 | -0.1706 |
| 3957 | LGALS2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.34e-04 | 7.82e-01 | -0.2061 |
| 3957 | LGALS2 | A015-C-204 | Human | Colorectum | FAP | 2.89e-02 | -1.24e-01 | -0.0228 |
| 3957 | LGALS2 | A002-C-201 | Human | Colorectum | FAP | 3.98e-02 | -1.10e-01 | 0.0324 |
| 3957 | LGALS2 | A001-C-108 | Human | Colorectum | FAP | 1.82e-03 | -1.24e-01 | -0.0272 |
| 3957 | LGALS2 | A002-C-205 | Human | Colorectum | FAP | 6.18e-04 | -1.24e-01 | -0.1236 |
| 3957 | LGALS2 | A001-C-104 | Human | Colorectum | FAP | 1.82e-03 | -1.24e-01 | 0.0184 |
| 3957 | LGALS2 | A002-C-114 | Human | Colorectum | FAP | 7.48e-03 | -1.24e-01 | -0.1561 |
| 3957 | LGALS2 | A018-E-020 | Human | Colorectum | FAP | 2.72e-03 | -1.24e-01 | -0.2034 |
| 3957 | LGALS2 | CRC-3-11773 | Human | Colorectum | CRC | 1.82e-03 | -1.24e-01 | 0.2564 |
| 3957 | LGALS2 | HTA12-26-1 | Human | Pancreas | PDAC | 9.84e-03 | -6.36e-01 | 0.3728 |
| 3957 | LGALS2 | HTA12-29-1 | Human | Pancreas | PDAC | 1.59e-13 | -6.36e-01 | 0.3722 |
| 3957 | LGALS2 | HTA12-9-1 | Human | Pancreas | PDAC | 1.91e-03 | -5.84e-01 | 0.1532 |
| 3957 | LGALS2 | 3829-EC | Human | Pancreas | PanIN | 2.65e-11 | -5.10e-01 | 0.009 |
| 3957 | LGALS2 | 4347-EC | Human | Pancreas | PanIN | 2.29e-11 | -4.01e-01 | 0.0572 |
| 3957 | LGALS2 | DS20191261Tumor | Human | Pancreas | PDAC | 3.25e-05 | -5.90e-01 | 0.1367 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LGALS2 | insertion | In_Frame_Ins | novel | c.191_192insGACTTCCAGCCGAGATTCTCTGTCCTGGTTCTTCTTCCGAGTCACACC | p.Asn64delinsLysThrSerSerArgAspSerLeuSerTrpPhePhePheArgValThrPro | p.N64delinsKTSSRDSLSWFFFRVTP | P05162 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| LGALS2 | SNV | Missense_Mutation | rs9607476 | c.73N>A | p.Ala25Thr | p.A25T | P05162 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| LGALS2 | SNV | Missense_Mutation | novel | c.263N>C | p.Phe88Ser | p.F88S | P05162 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
| LGALS2 | SNV | Missense_Mutation | c.295N>A | p.Asp99Asn | p.D99N | P05162 | protein_coding | tolerated(0.08) | possibly_damaging(0.734) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| LGALS2 | SNV | Missense_Mutation | novel | c.76N>T | p.Asp26Tyr | p.D26Y | P05162 | protein_coding | deleterious(0.01) | possibly_damaging(0.668) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LGALS2 | SNV | Missense_Mutation | novel | c.229N>C | p.Ser77Arg | p.S77R | P05162 | protein_coding | tolerated(0.12) | possibly_damaging(0.677) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| LGALS2 | SNV | Missense_Mutation | novel | c.334N>C | p.Ser112Arg | p.S112R | P05162 | protein_coding | tolerated(0.28) | possibly_damaging(0.621) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| LGALS2 | SNV | Missense_Mutation | novel | c.118G>A | p.Asp40Asn | p.D40N | P05162 | protein_coding | deleterious(0.05) | benign(0.023) | TCGA-D1-A2G5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| LGALS2 | SNV | Missense_Mutation | c.232C>A | p.Pro78Thr | p.P78T | P05162 | protein_coding | tolerated(0.12) | possibly_damaging(0.579) | TCGA-55-1592-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| LGALS2 | SNV | Missense_Mutation | c.148T>A | p.Phe50Ile | p.F50I | P05162 | protein_coding | deleterious(0.01) | possibly_damaging(0.654) | TCGA-64-5775-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | carboplatin | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3957 | LGALS2 | NA | MITOMYCIN C | 17999373 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |